Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2025 08:35 ET | Source: Straits Research Private Limited - Garner Insights

Idiopathic Pulmonary Fibrosis Market Size is Expected to Reach USD 9.23 Billion by 2033, Growing at a CAGR of 7.35%: Straits Research

New York, United States, March 06, 2025 (GLOBE NEWSWIRE) -- Idiopathic pulmonary fibrosis is a progressive, chronic lung disease that affects people aged 50 to 70. Breathlessness and a dry,...
March 30, 2022 16:05 ET | Source: Angion Biomedica Corp.

Angion Provides Corporate Update and Reports Full Year 2021 Financial Results

-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents ...
February 28, 2022 16:05 ET | Source: Angion Biomedica Corp.

Angion Announces Participation in Upcoming Investment Conferences

UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
January 04, 2022 16:05 ET | Source: Angion Biomedica Corp.

Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference

-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE,...
November 12, 2021 07:00 ET | Source: Angion Biomedica Corp.

Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results

UNIONDALE, N.Y., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
March 28, 2019 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Provides Management Team Updates

Mark Tepper, Ph.D., transitions to role of external Senior Scientific Advisor Robert Discordia, Ph.D., role expanded to lead Chemistry, Manufacturing and Controls operationsSergei Atamas, M.D.,...
March 11, 2016 08:00 ET | Source: FibroGen, Inc.

FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis

SAN FRANCISCO, March 11, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (FibroGen) announced today that the European Respiratory Journal (“ERJ”) published on-line a manuscript...